Varicella‐Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine
The Journal of Infectious Diseases2009Vol. 200(7), pp. 1068–1077
Citations Over TimeTop 10% of 2009 papers
Adriana Weinberg, Jane H. Zhang, Michael N. Oxman, Gary R. Johnson, Anthony Hayward, Michael J. Caulfield, Michael R. Irwin, J. Clair, Jeffrey G. Smith, Harold A. Stanley, Rocio D. Marchese, Ruth Harbecke, Heather Williams, Ivan S. F. Chan, Robert D. Arbeit, Anne A. Gershon, F. Schödel, Vicki A. Morrison, Carol A. Kauffman, Steve E. Straus, Kenneth E. Schmader, Larry E. Davis, Myron J. Levin
Abstract
Higher VZV CMI at HZ onset was associated with reduced HZ severity and less postherpetic neuralgia. Higher antibody titers were associated with increased HZ severity and occurrence of postherpetic neuralgia. HZ and zoster vaccine generated comparable VZV CMI.
Related Papers
- → Neurologic Complications of the Reactivation of Varicella–Zoster Virus(2000)846 cited
- → A real‐time PCR assay to identify and discriminate among wild‐type and vaccine strains of varicella‐zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses(2009)71 cited
- → Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia(2011)39 cited
- → Herpes zoster infection and postherpetic neuralgia(2001)15 cited